Interventional oncology ablation market

The global interventional oncology ablation market is estimated to be valued at US$ 533.7 Million in 2023 and is expected to exhibit a CAGR of 8.7% during the forecast period (2023-2030).

Analysts’ Views on Global Interventional Oncology Ablation Market:

Increasing product approvals by regulatory authorities is expected to propel the growth of the global interventional oncology ablation market over the forecast period. For instance, in September 2022,  Stryker, a leading medical technology company, received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its OptaBlate bone tumor ablation system. OptaBlate, a bone tumor ablation system with patented microinfusion technology, offers a reliable solution for people living with painful metastatic tumors.

Figure 1. Global Interventional Oncology Ablation Market Share (%), By Technology, 2023

Global Interventional Oncology Ablation Market– Drivers

• Increasing research and development activities by market players: Increasing research and development activities by market players is expected to propel the growth of the global interventional oncology ablation market over the forecast period. For instance, on July 19, 2023, Francis Medical, Inc., a medical device company, developed an innovative and proprietary water vapor ablation therapy for the treatment of prostate, kidney, and bladder cancer. The first patient has been treated in the company’s VAPOR 2 pivotal clinical study evaluating the safety and efficacy of its Vanquish minimally invasive water vapor ablation therapy for managing prostate cancer.          

Figure 2. Global Interventional Oncology Ablation Market Share (%), By Region, 2023

Global Interventional Oncology Ablation Market- Regional Analysis

Among regions, North America is estimated to hold a dominant position in the global interventional oncology ablation market over the forecast period. North America is estimated to hold 33.5% of the market share in 2023. Increasing product approvals by regulatory authorities are contributing to the growth of the global interventional oncology ablation market in the North America region. For instance, in September 2021, Novian Health Inc. a biotechnology company was granted Breakthrough Device designation from the U.S. Food and Drug Administration for its Novilase Interstitial Laser System and its proposed indication for use in focal destruction of malignant breast tumors in adult women who seek a breast conserving procedure.

Global Interventional Oncology Ablation Market– Impact of Coronavirus (COVID-19) Pandemic

• Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe, and the World Health Organization declared it a public health emergency on January 30, 2020.
• COVID-19 affected the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, the U.A.E., Egypt, and others, faced problems with the transportation of things from one place to another.
• The coronavirus, or COVID-19 outbreak, that started in Wuhan, China, has spread across continents, affecting various industries globally. The supply of key materials, such as probes required for interventional ablation, has been severely disrupted due to forced quarantines and lockdowns in various countries. This has led to disruptions in the link between regional warehouses, and the transportation of materials between regions cannot be carried out successfully. This shortage of probes required for interventional ablation materials and components used with the interventional ablation devices has affected the supply chain of the global interventional oncology ablation market.

Global Interventional Oncology Ablation Market Segmentation:

The global interventional oncology ablation market report is segmented by technology, by indication, by end user, and by region.

• By technology, the market is segmented into radiofrequency ablation, microwave ablation, cryoablation, and irreversible electroporation ablation. Out of which, the radiofrequency ablation is expected to hold a dominant position in the global interventional oncology ablation market during the forecast period, and this is attributed to the increasing product launches by market players.
• By Indication, the market is segmented into liver cancer, kidney cancer, lung cancer, and others. Out of which, lung cancer is expected to dominate the market over the forecast period, and this is attributed to increasing product launches for lung cancer.
• By end user, the market is segmented into hospitals & clinics, ambulatory surgical centers, and others. Out of which, hospitals is expected to dominate the market over the forecast period, and this is attributed to the prompt treatment that can lead to proper recovery.
• Among all the segmentation, the lung cancer segment is expected to dominate the market over the forecast period, and this is attributed to increasing research and development activities by market players. For instance, on March 7, 2023, Galvanize Therapeutics, Inc. a biomedical platform company presented data at SIR 2023, including PEF safety and feasibility results in patients with non-small cell lung cancer and pre-clinical results comparing PEF and radiofrequency ablation.

Global Interventional Oncology Ablation Market- Cross Sectional Analysis:

Among indication, liver cancer segment is expected to boost the interventional oncology ablation market in the North America region. For instance, in March 2022, Quantum Surgical SAS a medical robotics company received U.S. Food and Drug Administration (FDA) 510(k) clearance for Epione, a new category of interventional oncology robotics dedicated to minimally invasive liver cancer treatment. Epione is a unique robotic-assisted technology that can plan, target, deliver, and confirm tumor ablation.

Global Interventional Oncology Ablation Market: Key Developments

• On April 4, 2023, Ethicon, a part of Johnson & Johnson MedTech Company, announced the first patient treated in the North America with robot-assisted transbronchial microwave ablation as part of the global Ethicon POWER Study. The study involves leading global thoracic oncology centers and is intended to enroll patients with oligometastatic (OML) tumors in the lung.
• In December, 2022, Novian Health received Frost & Sullivan’s 2022 European New Product Innovation Award in the breast tumor ablation industry for its Novilase Breast Therapy system. Novilase is a laser ablation to destroy tumors as an alternative to surgery.
• In July 2022, Medtronic Plc medical device company introduced first-in-world lung ablation procedure with the ILLUMISITE fluoroscopic navigation platform. The ILLUMISITE platform navigates accurately to the most distant areas of the lung and can sample multi-directionally for a thorough biopsy.
• In September 2021, Boston Scientific Corporation a biotechnology company acquired Devoro Medical a medical device company to expand Boston Scientific's ablation portfolio with Devoro's WOLF TheraSphere microwave ablation system. It enhanced Boston Scientific's leadership in interventional oncology and ability to provide minimally invasive cancer care.
• In August 2021, AngioDynamics a medical technology company received U.S. Food and Drug Administration approval for its Exiru radiofrequency ablation system for treating lung tumors. This system uses advanced technology to ablate soft tissue with precision and control. The approval allowed AngioDynamics to enter the growing lung ablation market in the U.S.

Global Interventional Oncology Ablation Market: Key Trends

• Introduction of oncology ablation with advanced technology: The introduction of oncology ablation with advanced technology in the market is expected to drive the growth of the global interventional oncology ablation market over the forecast period. For instance, in September 2020, Ethicon found a new study in which Neuwave with Ablation Confirmation Software demonstrated improved procedural outcomes during liver tumor ablation procedures.

Global Interventional Oncology Ablation Market: Restraint

• Adverse events associated with radiofrequency (RF) ablation: Adverse events associated with radiofrequency (RF) ablation are expected to hinder market growth over the forecast period. For instance, Boston Scientific Corporation reported adverse events associated with radiofrequency (RF) ablation, including ARDS (acute respiratory distress syndrome), arrhythmia, hemorrhage, renal failure, tumor seeding and others. Key players are focusing on developing advanced products with safety to avoid these adverse events, which is expected to drive market growth over the forecast period.

Global Interventional Oncology Ablation Market - Key Players

Major players operating in the global interventional oncology ablation market include Boston Scientific Corporation, Johnson & Johnson, Medtronic Plc, Varian Medical Systems, Inc., EDAP TMS S.A., AngioDynamics, CASCINATION AG, Merit Medical Systems, Inc., STARmed Co., and Biomedical Srl.

Detailed Segmentation:

• Global Interventional Oncology Ablation Market, By Technology:
  • Radiofrequency Ablation
  • Microwave Ablation
  • Cryoablation
  • Irreversible Electroporation Ablation
• Global Interventional Oncology Ablation Market, By Indication:
  • Liver Cancer
  • Kidney Cancer
  • Lung Cancer
  • Others
• Global Interventional Oncology Ablation Market, By End User:
  • Hospitals & Clinics
  • Ambulatory Surgical Centers
  • Others
•  Global Interventional Oncology Ablation Market, By Region:
  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa